首页 > 最新文献

Oncology Research and Treatment最新文献

英文 中文
Colorectal Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2023. 欧洲肿瘤内科学会 2023 年年会的结直肠癌亮点。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-01 DOI: 10.1159/000538110
Ira Ekmekciu, Alexander Edward Nieto, Magdalena K Scheck, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Thorsten Oliver Götze, Henning Wege, Anke Reinacher-Schick, Sylvie Lorenzen, Ralf-Dieter Hofheinz, Greta Sommerhäuser
{"title":"Colorectal Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2023.","authors":"Ira Ekmekciu, Alexander Edward Nieto, Magdalena K Scheck, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Thorsten Oliver Götze, Henning Wege, Anke Reinacher-Schick, Sylvie Lorenzen, Ralf-Dieter Hofheinz, Greta Sommerhäuser","doi":"10.1159/000538110","DOIUrl":"10.1159/000538110","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data. 德国非住院常规肿瘤治疗:真实世界的生存数据。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-15 DOI: 10.1159/000536652
Norbert Marschner, Wolfgang Knauf

Introduction: Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare.

Methods: Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020. For these patients with advanced colorectal cancer, breast cancer, lung cancer, pancreatic cancer, renal cell cancer, and lymphatic neoplasms, overall survival was analysed. A comprehensive literature search was performed to identify suitable pivotal randomised controlled trials.

Results: Median overall survival of patients treated in German routine care, with advanced colorectal, breast, lung, and pancreatic cancer, as well as with diffuse large B-cell lymphoma and multiple myeloma, is not shorter than the respective survival data reported in trials. Patients with advanced renal cell carcinoma, chronic lymphocytic leukaemia, or indolent non-Hodgkin lymphoma showed slightly lower survival rates compared to clinical trials.

Conclusions: Despite less favourable patient characteristics, survival data from patients with cancer treated in ambulatory routine care in Germany are in range with results from randomised controlled studies.

简介随机对照试验报告的存活率数据是在经过严格筛选的患者群体中收集的,因此只能在一定程度上应用于现实世界中的患者:常规护理中的患者大多年龄较大,合并症较多,总体健康状况较差。这种所谓的疗效差距通常会导致常规医疗的生存数据较差:方法:2006 年至 2020 年间,六个前瞻性临床肿瘤登记处共招募了 11679 名在德国血液肿瘤诊所接受系统治疗的患者。对这些晚期结直肠癌、乳腺癌、肺癌、胰腺癌、肾细胞癌和淋巴肿瘤患者的总生存期进行了分析。为了找到合适的关键性随机对照试验,我们进行了全面的文献检索:结果:在德国接受常规治疗的晚期结直肠癌、乳腺癌、肺癌、胰腺癌以及弥漫大 B 细胞淋巴瘤和多发性骨髓瘤患者的中位总生存期并不比试验报告的相应生存期数据短。与临床试验相比,晚期肾细胞癌、慢性淋巴细胞白血病或非霍奇金淋巴瘤患者的生存率略低:结论:尽管患者的特征不太理想,但在德国接受非住院常规治疗的癌症患者的生存数据与随机对照研究的结果相符。
{"title":"Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.","authors":"Norbert Marschner, Wolfgang Knauf","doi":"10.1159/000536652","DOIUrl":"10.1159/000536652","url":null,"abstract":"<p><strong>Introduction: </strong>Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare.</p><p><strong>Methods: </strong>Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020. For these patients with advanced colorectal cancer, breast cancer, lung cancer, pancreatic cancer, renal cell cancer, and lymphatic neoplasms, overall survival was analysed. A comprehensive literature search was performed to identify suitable pivotal randomised controlled trials.</p><p><strong>Results: </strong>Median overall survival of patients treated in German routine care, with advanced colorectal, breast, lung, and pancreatic cancer, as well as with diffuse large B-cell lymphoma and multiple myeloma, is not shorter than the respective survival data reported in trials. Patients with advanced renal cell carcinoma, chronic lymphocytic leukaemia, or indolent non-Hodgkin lymphoma showed slightly lower survival rates compared to clinical trials.</p><p><strong>Conclusions: </strong>Despite less favourable patient characteristics, survival data from patients with cancer treated in ambulatory routine care in Germany are in range with results from randomised controlled studies.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geriatric Assessment Scale for Optimal Management of Gastric Cancer in Older Adults Who Underwent Gastrectomy: A Systematic Review. 老年评估量表用于对接受胃切除术的老年人进行胃癌优化管理:系统回顾 .
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-13 DOI: 10.1159/000539774
Brenda Rodriguez-Arroyo, Pedro Caraballo, Alejandro Pineda-Isaza, Oriana Arias-Valderrama, Manuel A Cleves, Angela R Zambrano

Introduction: Stomach cancer is one of the most common causes of cancer worldwide, especially in the population over 65 years. The survival rate of the elderly is lower in comparison with young people, and they are underrepresented in clinical trials and research in general. The evaluation of Multidimensional Geriatric Assessment (MGA) would be key for assessing the prognosis of these patients and therefore having a more informed decision-making process when considering one of the most vulnerable populations.

Methods: A search was performed in the OVID, Embase, and PubBMed databases. There was no restriction on publication time, language, or study design. Eligible studies were those that included geriatric patients with a diagnosis of nonmetastatic stomach cancer who receive oncospecific and surgical management, used Multidimensional/Comprehensive Geriatric Assessment (MGA), and which outcomes included at least overall survival, morbidity, and mortality.

Results: Four studies were included, and the MGA battery was not implemented, but rather easily measurable scales such as nutritional status, functional status, cognitive and behavioral disorders, comorbidities, and polypharmacy. Some authors proposed that the assessment of overall survival is not explicit among the included studies; patients with gastric cancer and mild, moderate, severe, and total dependence had higher mortality than independent patients (39% [HR 1.39; 95% CI: 1.09-1.7], 68% [95% CI: 1.46-1.93], 187% [HR 2.87 95% CI: 2.47-3.34], and 234% [95% CI: 2.81-3.97]), respectively. The Zhou study showed an association between sarcopenia, assessed by imaging studies, and a longer hospital stay in days (16 [9] vs. 13 [6], p 0.004). The study by Pujara found that polypharmacy (OR 2.36 CI: 1.08-5.17) and weight loss greater than 10% in the past 6 months were associated with greater postoperative morbidity at 90 days (OR 2.36 CI: 1.08-5.17, OR 11.21 CI: 2.16-58.24).

Conclusion: MGA was not broadly implemented. Geriatric assessment dependency appears to be a prognostic marker of survival in patients with gastric cancer. Sarcopenia appears to be an important prognostic marker for short- and long-term outcomes. Higher quality studies in this specific population are required to support the systematic use of this assessment for the choice of appropriate therapy according to the patient.

简介:胃癌是全球最常见的癌症之一,尤其是在 65 岁以上的人群中,生存率低于年轻人:胃癌是全球最常见的癌症之一,尤其是在65岁以上的人群中,其生存率低于年轻人,对老年病学的评估将是评估这些患者预后的关键:方法:在OVID、EMBASE和PUBMED数据库中进行了检索,在应用纳入和排除标准后,对4篇文章进行了分析:在纳入的研究中,没有使用 MGA 电池,而是使用了营养状况、功能状态、认知和行为障碍、合并症和多重用药等易于测量的量表,一些作者提出通过评估总生存率,但在纳入的研究中,胃癌患者和轻度、中度、重度和完全依赖者的死亡率高于独立患者(39% HR 1.39;95% CI 1.09-1.7)、68%(95% CI:1.46-1.93)、187%(HR 2.87 95% CI:2.47-3.34)和 234% 95% CI:2.81-3.97)。Zhou 的研究显示,通过影像学检查评估的肌少症与住院天数延长之间存在关联(16 [9] 对 13 [6],P 0.004)。Pujara 的研究发现,多药(OR 2.36 CI 1.08-5.17)和过去 6 个月体重下降超过 10%与 90 天的术后发病率增加有关(OR 2.36 CI 1.08-5.17,(OR 11.21 IC 2.16-58.24):老年病学评估依赖性似乎是胃癌患者生存期的预后指标,然而,需要对这一特定人群进行更高质量的研究,以支持系统性地使用这一评估,根据患者情况选择适当的治疗方法。
{"title":"Geriatric Assessment Scale for Optimal Management of Gastric Cancer in Older Adults Who Underwent Gastrectomy: A Systematic Review.","authors":"Brenda Rodriguez-Arroyo, Pedro Caraballo, Alejandro Pineda-Isaza, Oriana Arias-Valderrama, Manuel A Cleves, Angela R Zambrano","doi":"10.1159/000539774","DOIUrl":"10.1159/000539774","url":null,"abstract":"<p><strong>Introduction: </strong>Stomach cancer is one of the most common causes of cancer worldwide, especially in the population over 65 years. The survival rate of the elderly is lower in comparison with young people, and they are underrepresented in clinical trials and research in general. The evaluation of Multidimensional Geriatric Assessment (MGA) would be key for assessing the prognosis of these patients and therefore having a more informed decision-making process when considering one of the most vulnerable populations.</p><p><strong>Methods: </strong>A search was performed in the OVID, Embase, and PubBMed databases. There was no restriction on publication time, language, or study design. Eligible studies were those that included geriatric patients with a diagnosis of nonmetastatic stomach cancer who receive oncospecific and surgical management, used Multidimensional/Comprehensive Geriatric Assessment (MGA), and which outcomes included at least overall survival, morbidity, and mortality.</p><p><strong>Results: </strong>Four studies were included, and the MGA battery was not implemented, but rather easily measurable scales such as nutritional status, functional status, cognitive and behavioral disorders, comorbidities, and polypharmacy. Some authors proposed that the assessment of overall survival is not explicit among the included studies; patients with gastric cancer and mild, moderate, severe, and total dependence had higher mortality than independent patients (39% [HR 1.39; 95% CI: 1.09-1.7], 68% [95% CI: 1.46-1.93], 187% [HR 2.87 95% CI: 2.47-3.34], and 234% [95% CI: 2.81-3.97]), respectively. The Zhou study showed an association between sarcopenia, assessed by imaging studies, and a longer hospital stay in days (16 [9] vs. 13 [6], p 0.004). The study by Pujara found that polypharmacy (OR 2.36 CI: 1.08-5.17) and weight loss greater than 10% in the past 6 months were associated with greater postoperative morbidity at 90 days (OR 2.36 CI: 1.08-5.17, OR 11.21 CI: 2.16-58.24).</p><p><strong>Conclusion: </strong>MGA was not broadly implemented. Geriatric assessment dependency appears to be a prognostic marker of survival in patients with gastric cancer. Sarcopenia appears to be an important prognostic marker for short- and long-term outcomes. Higher quality studies in this specific population are required to support the systematic use of this assessment for the choice of appropriate therapy according to the patient.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contents Vol. 46, 2023 目录46, 2023
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535561
J. P. Klussmann, Marcus Schmidt, Matthias Theobald – Third, Peter Albers, Dirk Arnold, D’Andrea, M. A. Reddy, TX G.K. Houston, Therapeutischer Ansatzpunkt, Immunsystem
{"title":"Contents Vol. 46, 2023","authors":"J. P. Klussmann, Marcus Schmidt, Matthias Theobald – Third, Peter Albers, Dirk Arnold, D’Andrea, M. A. Reddy, TX G.K. Houston, Therapeutischer Ansatzpunkt, Immunsystem","doi":"10.1159/000535561","DOIUrl":"https://doi.org/10.1159/000535561","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139021269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AbbVie: BioPharma-Unternehmen mit onkologischer Mission 艾伯维:肩负肿瘤使命的生物制药公司
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535453
Pflichttext Epcoritamab, Pflichttext Venetoclax
{"title":"AbbVie: BioPharma-Unternehmen mit onkologischer Mission","authors":"Pflichttext Epcoritamab, Pflichttext Venetoclax","doi":"10.1159/000535453","DOIUrl":"https://doi.org/10.1159/000535453","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139024835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
uGI: Biomaker-Cut-Offs in der Immunonkologie uGI:免疫肿瘤学中的生物标记物临界值
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535307
{"title":"uGI: Biomaker-Cut-Offs in der Immunonkologie","authors":"","doi":"10.1159/000535307","DOIUrl":"https://doi.org/10.1159/000535307","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139014148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCC - Frühzeitiges Erkennen ermöglicht rasche und effektive Therapie HCC - 早期检测可实现快速有效的治疗
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535417
{"title":"HCC - Frühzeitiges Erkennen ermöglicht rasche und effektive Therapie","authors":"","doi":"10.1159/000535417","DOIUrl":"https://doi.org/10.1159/000535417","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4-Jahres-Daten der CheckMate-9LA-Studie zum NSCLC CheckMate 9LA NSCLC 研究的 4 年数据
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535447
{"title":"4-Jahres-Daten der CheckMate-9LA-Studie zum NSCLC","authors":"","doi":"10.1159/000535447","DOIUrl":"https://doi.org/10.1159/000535447","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacituzumab govitecan beim fortgeschrittenen Mammakarzinom 萨妥珠单抗戈维替康治疗晚期乳腺癌
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535408
{"title":"Sacituzumab govitecan beim fortgeschrittenen Mammakarzinom","authors":"","doi":"10.1159/000535408","DOIUrl":"https://doi.org/10.1159/000535408","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum 勘误表
IF 2.4 4区 医学 Q3 Medicine Pub Date : 2023-08-29 DOI: 10.1159/000530178
{"title":"Erratum","authors":"","doi":"10.1159/000530178","DOIUrl":"https://doi.org/10.1159/000530178","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43009879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncology Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1